Zacks: Brokerages Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Earnings of -$0.05 Per Share
Equities research analysts forecast that VistaGen Therapeutics, Inc. (NASDAQ:VTGN) will report ($0.05) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for VistaGen Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.04). VistaGen Therapeutics reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive year over year growth rate of 61.5%. The company is scheduled to report its next quarterly earnings report on Monday, July 5th.
According to Zacks, analysts expect that VistaGen Therapeutics will report full year earnings of ($0.23) per share for the current year, with EPS estimates ranging from ($0.24) to ($0.22). For the next year, analysts anticipate that the business will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.41) to ($0.22). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for VistaGen Therapeutics.
VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, February 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.33 million.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC purchased a new position in VistaGen Therapeutics in the 4th quarter valued at about $14,550,000. Acuta Capital Partners LLC acquired a new stake in shares of VistaGen Therapeutics during the fourth quarter worth approximately $14,550,000. Ikarian Capital LLC bought a new position in VistaGen Therapeutics during the 4th quarter worth $8,703,000. Ghost Tree Capital LLC bought a new stake in VistaGen Therapeutics during the fourth quarter worth $4,734,000. Finally, Asymmetry Capital Management L.P. purchased a new position in VistaGen Therapeutics during the fourth quarter valued at $4,345,000. Hedge funds and other institutional investors own 3.13% of the company’s stock.
Shares of NASDAQ VTGN traded down $0.07 during mid-day trading on Tuesday, reaching $2.59. The company had a trading volume of 2,353,512 shares, compared to its average volume of 3,166,321. The stock has a market cap of $371.25 million, a P/E ratio of -5.40 and a beta of 0.52. The firm has a 50 day simple moving average of $2.19 and a two-hundred day simple moving average of $1.70. VistaGen Therapeutics has a 52-week low of $0.35 and a 52-week high of $3.18.
About VistaGen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.
Read More: Cash Flow Analysis in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.